Article
In a new development in the ongoing controversy regarding the use of transvaginal mesh, the American Urogynecologic Society has released a position statement against bans of surgical options such as mesh.
In a new development in the ongoing controversy regarding the use of transvaginal mesh, the American Urogynecologic Society has released a position statement against bans of surgical options such as mesh.
"The American Urogynecologic Society strongly opposes any restrictions by state or local medical organizations, healthcare systems, or insurance companies which ban currently available surgical options performed by qualified and credentialed surgeons on appropriately informed patients with pelvic floor disorders," the statement reads.
In a letter to AUGS members regarding the position statement, AUGS President Anthony G. Visco, MD, explained that in recent months, a state medical organization, a health care system, and a malpractice insurance company have considered restricting or have banned the use of transvaginal mesh for prolapse.
"A ban on mesh would have a chilling effect on research in this area and would severely limit the advancement of science and future innovations that could significantly help women. We recommend preserving all surgical options, including transvaginal mesh for pelvic organ prolapse, adopting recently published credentialing guidelines, standardizing the informed consent process, and establishing a robust mechanism to track both surgeons and products being implanted to fully assess safety and efficacy," Dr. Visco said in the letter.
AUGS provided several justifications for the position statement, including:
"It is imperative that local hospitals and health systems establish and strictly enforce robust processes to both credential and audit surgeons with specific expertise, experience, training, and skill to perform these procedures," AUGS said in the position statement.
Related Content
Transvaginal mesh controversy: Careful patient selection is key